Efficacy
After a median follow up 15.6 (range, 0-28.6) months, the median overall survival (OS) was 19.2 months (95% CI 17.0-23.7) with atezolizumab plus bevacizumab and 13.4 months (95% CI 11.4-16.9) with sorafenib (hazard ratio (HR) 0.66 95% CI 0.52 - 0.85, P>0.001). Survival rates at 12 and 18 months respectively were 67% and 52% for patients in the atezolizumab plus bevacizumab arm, and 56% and 40% for patients in the sorafenib arm.
The median PFS was 6.9 (95% CI 5.7 - 8.6) for atezolizumab plus bevacizumab and 4.3 (95% CI 4.0 - 5.6) months in the sorafenib group (HR 0.65 95% CI 0.53-0.81 descriptive P>0.001).
Confirmed objective responses occured in 97 of 326 (30%) patients (95% CI 25-35) treated with atezolizumab plus bevaczumab vs 18 of 159 (11%) patients (95% CI 7-17) in the sorafenib group. 8% had a complete response with atezolizumab plus bevacizumab vs < 1% with sorafenib.r
Kaplan-Meier curve of (A) OS (B) PFSr
© J Hepatol 2022
Summary of Resultsr
© J Hepatol 2022
Patient-reported quality of life was collected for >80% of patient in this trial. Measures were favourable in the atezolizumab–bevacizumab group, with delayed deterioration of patient-reported quality of life (median time to deterioration, 11.2 months with atezolizumab–bevacizumab vs. 3.6 months with sorafenib; hazard ratio, 0.63; 95% CI, 0.46 to 0.85).r